VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa